Benzinga's Top Upgrades, Downgrades For January 24, 2018

Jefferies upgraded McKesson Corporation MCK from Hold to Buy. McKesson shares rose 1.55 percent to $173.25 in pre-market trading.
Morgan Stanley upgraded Energen Corporation EGN from Equal-Weight to Overweight. Energen fell 0.84 percent to $57.72 in pre-market trading.
Analysts at BMO Capital upgraded Berry Global Group Inc BERY from Market Perform to Outperform. Berry Global shares rose 1.37 percent to $59.03 in pre-market trading.
Stifel Nicolaus upgraded Casella Waste Systems Inc. CWST from Hold to Buy. Casella Waste Systems shares gained 0.37 percent to close at $24.26 on Tuesday.
Analysts at KeyBanc upgraded McDermott International Inc MDR from Sector Weight to Overweight. McDermott shares gained 4.96 percent to $8.25 in pre-market trading.
Analysts at Longbow Research upgraded Meritor Inc MTOR from Neutral to Buy. Meritor shares rose 4.7 percent to $24.95 in pre-market trading.
Macquarie upgraded Canadian National Railway (USA) CNI from Neutral to Outperform. Canadian National Railway shares gained 0.51 percent to close at $80.31 on Monday.
Analysts at Bank of America upgraded Louisiana-Pacific Corporation LPX from Underperform to Neutral. Louisiana-Pacific shares rose 0.24 percent to close at $37.82 on Monday.
Bank of America upgraded Weyerhaeuser Co WY from Neutral to Buy. Weyerhaeuser shares rose 1.12 percent to $37.02 in pre-market trading.

Analysts at Evercore ISI Group downgraded United Continental Holdings Inc UAL from Outperform to In-Line. United Continental shares fell 7.53 percent to $72.10 in pre-market trading.
Oppenheimer downgraded CEVA, Inc. CEVA from Outperform to Perform. CEVA shares rose 0.10 percent to close at $48.35 on Tuesday.
DZ Bank downgraded Visa Inc V from Buy to Hold. Visa shares rose 0.28 percent to close at $125.00 on Monday.
Argus downgraded Bioverativ Inc BIVV from Buy to Hold. Bioverativ shares fell 0.61 percent to close at $103.16 on Tuesday.
Mizuho downgraded PRA Health Sciences Inc PRAH from Buy to Neutral. PRA Health shares dropped 0.15 percent to close at $94.22 on Tuesday.
Barclays downgraded Juno Therapeutics Inc JUNO from Overweight to Equal-Weight. Juno Therapeutics shares fell 0.07 percent to $85.80 in pre-market trading.
Loop Capital downgraded Aaron's, Inc. AAN from Buy to Hold. Aaron's shares fell 1 percent to $41.69 in pre-market trading.
Analysts at Cowen & Co. downgraded Puma Biotechnology Inc PBYI from Outperform to Market Perform. Puma Biotechnology shares fell 27.89 percent to $65.55 in pre-market trading.
Morgan Stanley downgraded Encana Corp (USA) ECA from Overweight to Equal-Weight. Encana shares rose 0.37 percent to $13.60 in pre-market trading.
JMP Securities downgraded Jones Lang LaSalle Inc JLL from Market Outperform to Market Perform. Jones Lang LaSalle shares rose 0.10 percent to close at $156.14 on Monday.

Goldman Sachs initiated coverage on Valeant Pharmaceuticals Intl Inc VRX with a Sell rating. The price target for Valeant is set to $18. Valeant shares closed at $22.30 on Tuesday.
Taglich Brothers initiated coverage on Borqs Technologies, Inc. BRQS with a Speculative Buy rating. Borqs Technologies shares closed at $6.45 on Tuesday.
Nomura initiated coverage on Red Hat Inc RHT with a Buy rating. The price target for Red Hat is set to $152. Red Hat shares closed at $128.15 on Tuesday.
SunTrust Robinson Humphrey initiated coverage on Trivago NV - ADR TRVG with a Hold rating. Trivago shares closed at $7.65 on Tuesday.
Analysts at Nomura initiated coverage on Microsoft Corporation MSFT with a Buy rating. The price target for Microsoft is set to $102. Microsoft shares closed at $91.90 on Tuesday.
Analysts at Jefferies initiated coverage on HollyFrontier Corp HFC with an Underperform rating. The price target for HollyFrontier is set to $40. HollyFrontier shares closed at $51.72 on Tuesday.
Nomura initiated coverage on Oracle Corporation ORCL with a Buy rating. The price target for Oracle is set to $64. Oracle shares closed at $51.12 on Tuesday.
Analysts at Goldman Sachs initiated coverage on Halozyme Therapeutics, Inc. HALO with a Neutral rating. The price target for Halozyme Therapeutics is set to $20. Halozyme Therapeutics shares closed at $19.68 on Tuesday.

Analyst Calendar